Please enter the email address you used to register, then we will send you a link to choose a new password
Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...
- SEC Filing
Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...